Frank Mott
Overview
Explore the profile of Frank Mott including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
124
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Piha-Paul S, Xu B, Dumbrava E, Fu S, Karp D, Meric-Bernstam F, et al.
Oncologist
. 2024 Feb;
29(4):e514-e525.
PMID: 38297981
Purpose: This first-in-human phase I dose-escalation study evaluated the safety, pharmacokinetics, and efficacy of tinengotinib (TT-00420), a multi-kinase inhibitor targeting fibroblast growth factor receptors 1-3 (FGFRs 1-3), Janus kinase 1/2,...
2.
Yennurajalingam S, Mott F, Lu Z, Urbauer D, Stanton P, Torres H, et al.
Asia Pac J Oncol Nurs
. 2024 Jan;
10(Suppl 1):100314.
PMID: 38197040
Objective: Cancer cachexia (CC) is a frequent and debilitating syndrome in patients with cancer. It has serious implications for patients, extending beyond physical problems into psychological, and social domains. The...
3.
Singhi E, Mott F, Worst M, Leung C, Lee J, Carter B, et al.
Oncol Lett
. 2023 May;
25(6):262.
PMID: 37216156
Immunotherapy is an effective and generally well-tolerated treatment strategy for older adult patients (aged ≥70 years) with advanced non-small cell lung cancer (NSCLC). Unfortunately, most patients who receive immunotherapy eventually...
4.
Ferrarotto R, Sousa L, Feng L, Mott F, Blumenschein G, Altan M, et al.
J Clin Oncol
. 2023 Mar;
41(15):2843-2851.
PMID: 36898078
Purpose: We conducted a phase II trial evaluating the efficacy of VEGFR inhibitor axitinib and PD-L1 inhibitor avelumab in patients with recurrent/metastatic adenoid cystic carcinoma (R/M ACC). Patients And Methods:...
5.
Cognetti D, Johnson J, Curry J, Kochuparambil S, McDonald D, Mott F, et al.
Head Neck
. 2021 Oct;
43(12):3875-3887.
PMID: 34626024
Background: Recurrent head and neck squamous cell carcinoma (rHNSCC) represents a significant global health burden with an unmet medical need. In this study we determined the safety and efficacy of...
6.
Pelster M, Mott F, Lewin J
Laryngoscope
. 2019 May;
130(4):E140-E143.
PMID: 31074845
Pembrolizumab, an anti-PD-1 checkpoint inhibitor, is used in patients with recurrent or metastatic squamous cell carcinoma of the head and neck who have received prior therapy with a platinum-based regimen....
7.
Zhao J, Xia Y, Kaminski J, Hao Z, Mott F, Campbell J, et al.
PLoS One
. 2016 Jun;
11(6):e0157455.
PMID: 27300551
Treatment related death (TRD) is the worst adverse event in chemotherapy and radiotherapy for patients with cancer, the reports for TRDs were sporadically. We aimed to study TRDs in non-small...
8.
9.
Socoteanu M, Mott F, Alpini G, Frankel A
World J Gastroenterol
. 2008 May;
14(19):2990-4.
PMID: 18494048
Cholangiocarcinoma continues to be a challenging disease to treat. Systemic therapy is used in unresectable disease, disease progression after surgery, and in the palliative setting. Unfortunately, results of multiple phase...
10.
Marcus J, Elkins G, Mott F
Integr Cancer Ther
. 2004 Jan;
2(4):365-70.
PMID: 14713329
There exists a need for a broad and inclusive model of integration of mind-body interventions for palliative care. Symptoms relating to psychological distress and existential concerns are even more prevalent...